Amneal Pharmaceuticals, Inc.
AMRX
$11.94
-$0.18-1.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.05% | 9.50% | 9.81% | 13.42% | 16.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.05% | 9.50% | 9.81% | 13.42% | 16.73% |
| Cost of Revenue | 6.23% | 8.22% | 7.92% | 13.70% | 16.32% |
| Gross Profit | 11.22% | 11.71% | 13.13% | 12.94% | 17.45% |
| SG&A Expenses | 10.56% | 11.47% | 8.64% | 9.55% | 10.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -463.44% | -463.33% | -3,656.07% | -3,407.53% | 18.28% |
| Total Operating Expenses | 6.23% | 9.02% | 9.00% | 12.77% | 15.24% |
| Operating Income | 20.76% | 12.79% | 15.43% | 18.06% | 28.37% |
| Income Before Tax | 353.05% | 155.75% | 177.24% | 154.52% | -36.61% |
| Income Tax Expenses | -40.22% | -52.68% | 116.47% | 83.46% | 123.18% |
| Earnings from Continuing Operations | 273.17% | 139.34% | 138.47% | 126.95% | -51.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -29.91% | -36.19% | -15.58% | 6.03% | -21.94% |
| Net Income | 161.65% | 103.20% | 101.93% | 92.27% | -39.16% |
| EBIT | 20.76% | 12.79% | 15.43% | 18.06% | 28.37% |
| EBITDA | 10.21% | 10.05% | 12.79% | 13.03% | 16.73% |
| EPS Basic | 160.51% | 102.62% | 101.59% | 92.50% | -22.41% |
| Normalized Basic EPS | 395.73% | 369.08% | -25.56% | -578.72% | -290.55% |
| EPS Diluted | 159.26% | 102.39% | 101.34% | 92.56% | -20.20% |
| Normalized Diluted EPS | 385.54% | 339.47% | -39.01% | -588.42% | -290.05% |
| Average Basic Shares Outstanding | 1.42% | 6.76% | 22.67% | 44.32% | 75.61% |
| Average Diluted Shares Outstanding | 4.29% | 8.59% | 22.94% | 45.85% | 75.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |